Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Mauri

Showing results (221-230 of 335) with videos related to

Pageof 34
Sort By:
International Journal of Molecular Sciences|April 25, 2020
GM1 Oligosaccharide Crosses the Human Blood-Brain Barrier In Vitro by a Paracellular RouteErika Di Biase, Giulia Lunghi, Margherita Maggioni, et al.
Journal of Cardiovascular Computed Tomography|September 21, 2011
Rationale and design of the DeFACTO (Determination of Fractional Flow Reserve by Anatomic Computed Tomographic AngiOgraphy) studyJames K Min, Daniel S Berman, Matthew J Budoff, et al.
Circulation|July 21, 2020
Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT StudyKamil F Faridi, Hector Tamez, Jordan B Strom, et al.
JAMA Cardiology|July 21, 2016
Comparing Inverse Probability of Treatment Weighting and Instrumental Variable Methods for the Evaluation of Adenosine Diphosphate Receptor Inhibitors After Percutaneous Coronary InterventionJerome J Federspiel, Kevin J Anstrom, Ying Xian, et al.
Glycoconjugate Journal|July 15, 2025
Effects of GM1 ganglioside and its derivatives on ETI-rescued F508del-CFTR maturation and host-pathogen interactions in cystic fibrosis bronchial cellsDorina Dobi, Alessandro Rimessi, Nicoletta Loberto, et al.
Circulation. Cardiovascular Interventions|January 16, 2014
Causes of short-term readmission after percutaneous coronary interventionJason H Wasfy, Jordan B Strom, Cashel O'Brien, et al.
Journal of the American College of Cardiology|December 5, 2016
Cangrelor Use Since FDA Approval: A Single-Center, Real-World Experience at a Tertiary Care HospitalMuthiah Vaduganathan, Arman Qamar, Abhayjit Singh, et al.
JACC. Cardiovascular Interventions|January 23, 2016
Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting StentsJames B Hermiller, Mitchell W Krucoff, Dean J Kereiakes, et al.
JACC. Cardiovascular Interventions|March 26, 2013
Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE programSigmund Silber, Patrick W Serruys, Martin B Leon, et al.
International Journal of Molecular Sciences|July 1, 2020
GM1 as Adjuvant of Innovative Therapies for Cystic Fibrosis DiseaseGiulia Mancini, Nicoletta Loberto, Debora Olioso, et al.
Pageof 34

Showing results (221-230 of 335) with videos related to

Sort By:
Pageof 34
International Journal of Molecular Sciences|April 25, 2020
GM1 Oligosaccharide Crosses the Human Blood-Brain Barrier In Vitro by a Paracellular RouteErika Di Biase, Giulia Lunghi, Margherita Maggioni, et al.
Journal of Cardiovascular Computed Tomography|September 21, 2011
Rationale and design of the DeFACTO (Determination of Fractional Flow Reserve by Anatomic Computed Tomographic AngiOgraphy) studyJames K Min, Daniel S Berman, Matthew J Budoff, et al.
Circulation|July 21, 2020
Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT StudyKamil F Faridi, Hector Tamez, Jordan B Strom, et al.
JAMA Cardiology|July 21, 2016
Comparing Inverse Probability of Treatment Weighting and Instrumental Variable Methods for the Evaluation of Adenosine Diphosphate Receptor Inhibitors After Percutaneous Coronary InterventionJerome J Federspiel, Kevin J Anstrom, Ying Xian, et al.
Glycoconjugate Journal|July 15, 2025
Effects of GM1 ganglioside and its derivatives on ETI-rescued F508del-CFTR maturation and host-pathogen interactions in cystic fibrosis bronchial cellsDorina Dobi, Alessandro Rimessi, Nicoletta Loberto, et al.
Circulation. Cardiovascular Interventions|January 16, 2014
Causes of short-term readmission after percutaneous coronary interventionJason H Wasfy, Jordan B Strom, Cashel O'Brien, et al.
Journal of the American College of Cardiology|December 5, 2016
Cangrelor Use Since FDA Approval: A Single-Center, Real-World Experience at a Tertiary Care HospitalMuthiah Vaduganathan, Arman Qamar, Abhayjit Singh, et al.
JACC. Cardiovascular Interventions|January 23, 2016
Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting StentsJames B Hermiller, Mitchell W Krucoff, Dean J Kereiakes, et al.
JACC. Cardiovascular Interventions|March 26, 2013
Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE programSigmund Silber, Patrick W Serruys, Martin B Leon, et al.
International Journal of Molecular Sciences|July 1, 2020
GM1 as Adjuvant of Innovative Therapies for Cystic Fibrosis DiseaseGiulia Mancini, Nicoletta Loberto, Debora Olioso, et al.
Pageof 34